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Cardiometabolic treatment decisions in patients with
type 2 diabetes: the role of repeated measurements
and medication burden
J Voorham,1,2 F M Haaijer-Ruskamp,1 B H R Wolffenbuttel,3 R P Stolk,2 P Denig,1
Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) Group
ABSTRACT
Purpose Clinical guidelines for cardiometabolic risk
management indicate a simple threshold-based strategy
for treatment, but physicians and their patients may be
reluctant to modify drug treatment after a single elevated
measurement. We determined how repeated
measurements of blood pressure, cholesterol and
haemoglobin A1c affect general practitioners’ decisions
to start or intensify medication in patients with type 2
diabetes. We also evaluated whether medication burden
altered these decisions.
MethodsWe conducted a cohort study in 3029 patients
managed by 62 general practitioners (GPs). We
assessed the predictive value of the last risk factor
measurement, the number of successive measurements
above target level and the percentage change between
the last two measurements. Medication burden was
assessed as the number of drugs concurrently used.
Effects on treatment decisions were estimated by
multilevel logistic regression analysis, correcting for
clustering at GP level.
Results Repeated high levels of diastolic blood pressure
increased the likelihood to start antihypertensive
medication (OR¼2.08, CI 1.37 to 3.17). Repeated high
haemoglobin A1c levels affected intensification of oral
glucose-lowering medication (OR¼1.71, CI 1.44 to 2.03).
Modification of lipid-lowering medication was limited, and
only affected by the last total cholesterol level. Starting
treatment for all three risk factors, as well as intensifying
antihypertensive treatment, was more likely in patients
already using more drugs for other chronic diseases.
Conclusions Waiting for the next measurement before
deciding to change medication can explain in part the
apparent undertreatment for hypertension and
hyperglycaemia, but not for hypercholesterolaemia.
Medication burden was not a barrier for treatment
modification.
Adequate treatment of cardiometabolic risk factors
in patients with diabetes is important.1 Clinical
guidelines describe strict target levels above which
pharmacotherapy should be started or intensiﬁed.
Although considerable progress has been achieved in
the quality of diabetes care, undertreatment still
remains a concern.2e5
Several reasons for undertreatment have been
identiﬁed, including concerns about polypharmacy,
medication adherence, intolerance and costs.6e9
Postponing treatment intensiﬁcation because of
improvement already being made or competing
demands are other commonly reported reasons.9e14
Physicians may be reluctant to modify treatment
after a single elevated measurement.11 12 15 16
Especially, in patients with low overall risk, this
could be the case. Furthermore, in older patients
using multiple medications, a conservative
approach could be motivated by fears of medication
burden.8 9 13 17
Despite this rationale for awaiting a next obser-
vation before deciding to intervene, few studies
include more than one observation moment to
assess appropriate action. Studies that did include
a follow-up period suggest that physicians take
more than one measurement outcome into account
when making treatment decisions.12 18 19
The objective of this study is to investigate the
decisions of general practitioners (GPs) to start or
intensify medication treatment in patients with
type 2 diabetes and determine how repeated
measurements of blood pressure, cholesterol and
haemoglobin A1c (HbA1c) levels contribute to
these decisions. We evaluated whether the treat-
ment decisions are associated with the number of
previous measurements above target level, with
recent improvement or worsening of the risk factor,
as well as with any other of the three risk factors.
This will give insight in the inﬂuence of each of
these factors on the decision-making process. We
further tested whether medication burden affects
this decision and whether the risk factors are
weighed differently for patients with a high or low
overall risk.
METHODS
Study population and setting
Our study population comprised 3029 patients
who were managed for their diabetes by 1 of 62 GPs
participating in a regional diabetes project in the
northern Netherlands in 2004 and 2005. Twenty-
seven per cent of the GPs were female, and the
mean age was 49 years for male subjects and
43 years for female patients. Twenty-ﬁve (18%)
practised alone, six (10%) in a duo practice and 31
(50%) worked in a group practice. Of the 45 general
practices, 13 (29%) were located in rural areas and
were allowed to dispense drugs. All their patients
whom they managed themselves with a diagnosis
of type 2 diabetes at the beginning of the study
period were included.
In The Netherlands, nearly all inhabitants are
registered with a GP, who is the gatekeeper of the
healthcare system. In our study area, a regional dia-
betes facility offers support to GPs. Patients can be
referred to this facility for physical examination and
< A supplementary appendix is
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laboratory tests. The results are reported back to the GPs who
remain responsible for further treatment and treatment modiﬁ-
cations.Diabetespatients usually visit theirGPevery 3 months for
a check-up and medication reﬁlls. During the study period, there
were no governmental or insurance restrictions on the prescrip-
tion or reimbursement for the drugs included in our study.
Design and data collection
We conducted a cohort study to assess the inﬂuence of repeated
risk factor measurements on the decision to modify antihyper-
tensive, lipid-lowering and oral blood-glucose-lowering treat-
ment. Clinical measurements, comorbidity, prescriptions and
demographic data were collected from November 2001 until
March 2005. All information was extracted from electronic
patient record systems at the GPs’ ofﬁces and the regional
diabetes facility using a validated software programme.20 All GPs
in our study prescribe electronically, ensuring complete
prescribing information. For research using anonymous medical
records no ethics committee approval is needed in The
Netherlands.21
Outcome measures
Treatment modiﬁcation was the studied endpoint, deﬁned as the
ﬁrst treatment start or intensiﬁcation between October 2003
and September 2004. Patients were considered to start treatment
when they received a ﬁrst prescription after receiving no
prescriptions for that therapeutic group during the previous
6 months (twice the duration of a standard prescription for
chronic medication in The Netherlands). A modiﬁcation was
considered intensiﬁcation when a new drug class was added or
the medication dosage was increased. A switch to another drug
class, that is, starting a new drug when the original medication
was not continued within 120 days from the calculated end date,
was not considered treatment intensiﬁcation.
Patients with incomplete follow-up to assess treatment
intensiﬁcation and patients receiving maximal medication at
baseline were excluded from the analyses. The deﬁnitions for
maximal medication were derived from the Dutch Pharmaco-
therapy Compendium22 and prevailing national practice guide-
lines for GPs and at the time of the study.23e25 For
antihypertensive treatment, three drugs from different classes
prescribed at maximum maintenance dosage or more than three
drugs was considered maximal medication. For lipid-lowering
treatment, prescribing one drug at maximum dosage or more
than one drug was considered maximal medication. For glucose-
lowering treatment, insulin use was seen as maximal medication.
Predictors
As predictors of treatment modiﬁcations, we included the most
recent measurements of systolic and diastolic blood pressure,
total serum cholesterol, and HbA1c (called “last value”) and two
aspects of previous risk factor information: (1) the number of last
successive measurements above target level (called “intensity”)
and (2) per cent change in risk factor level, that is, the relative
difference between the last two measurements (called “change”).
Measurements in the preceding year were included for blood
pressure and HbA1c, and 2 years for total cholesterol since this
was usually measured once a year. Target levels were derived from
the practice guidelines at the time of our study: systolic blood
pressure<140 mm Hg, diastolic blood pressure<90 mm Hg,
total cholesterol<5.0 mmol/l and HbA1c<7.0%.23e25
Medication burden was assessed by counting unique drugs
prescribed in6 months up to themedication change, separately for
risk factor speciﬁc drugs and drugs for other chronic diseases. This
included all drugs at the lowest level of the Anatomical Thera-
peutic Chemical classiﬁcation system in classes A, B, C, H, L,M, N
or R.26 Fixed combinations of drugs were counted as one drug.
Analysis
Multilevel logistic regression was used, correcting for clustering
by allowing a random effect at GP level. We performed complete
subject analyses, enabling us to draw conclusions on the inﬂu-
ence of the risk factor information when available on the
treatment decisions. We constructed separate predictive models
for starting and intensifying treatment, adjusted for age, sex,
diabetes duration, albuminuria, body mass index, coronary
comorbidity (angina pectoris, myocardial infarction, heart
failure, coronary artery bypass graft, coronary angioplasty,
atrium ﬁbrillation) and other diabetes-related conditions (stroke,
transient ischaemic attack, peripheral arterial disease,
neuropathy, amputations, retinopathy). Interaction terms
between the predictors and sex/age were explored, and regres-
sion models were checked for collinearity. Overall models and
models stratiﬁed on cardiovascular risk were built. Risk strati-
ﬁcation was based on UKPDS 10-year cardiovascular risk scores
(low-risk<20%, high-risk$20%).27
RESULTS
The patients were aged 66 (12) years, and 56% were female. At
baseline, 14% had a noted history of coronary comorbidity, and
13% suffered from other diabetes-related conditions. The median
number of concurrently prescribed chronic drugs was 4. Risk
factor measurements were available in 75% to 82% of the cases
(table 1).
Treatment
Of the 3029 patients in our study population, 63%, 31% and
80% were using antihypertensive, lipid-lowering and glucose-
lowering medication at baseline, respectively. During the study
period, treatment was started for 8%, 11% and 7% of the
patients untreated at baseline. Of patients treated at baseline,
16%, 0.2% and 13% were already on maximal treatment.
Treatment intensiﬁcations were seen in another 15%, 5% and
30% of the patients already treated. In 49%, 66% and 73% of the
cases, intensiﬁcation was achieved without increasing the
number of drugs.
Predictors of treatment modification
The results of the regression models are presented in ﬁgure 1, and
the numerical information is available in the online appendix to
this paper.
For starting antihypertensive treatment, the level of the last
systolic blood pressure (p¼0.001) and repeated high levels of
diastolic blood pressure (p¼0.001) were independent predictors.
Treatment intensiﬁcation was more likely when the most recent
systolic (p¼0.002) or diastolic blood pressure (p¼0.021)
measurements were higher but was not affected by previous
measurements. The likelihood to start or intensify lipid-lowering
medication was also only affected by the level of the last
cholesterol measurement (p<0.001 and p¼0.002). Starting or
intensifying glucose-lowering medication was strongly associ-
ated with the level of the last HbA1c measurement (p<0.001 for
both), but repeated high HbA1c levels (p<0.001) and a recent
increase in HbA1c (p¼0.002) also increased the likelihood of
treatment intensiﬁcation.
There was no signiﬁcant inﬂuence of any of the other risk
factor levels on the treatment decisions. In patients already
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using more drugs for other chronic diseases, starting treatment
for all three risk factors (p<0.001) and intensiﬁcation of anti-
hypertensive treatment (p<0.001) was more likely. The number
of risk factor speciﬁc drugs already prescribed did not inﬂuence
the likelihood of treatment modiﬁcation.
The stratiﬁed analyses on overall cardiovascular risk showed
essentially the same predictors for starting and intensifying
medication with some shifts between the strata (online
appendix). Compared to the associations found in the total
patient group, the association of the last value of systolic blood
pressure with the start of treatment increased in the high-risk
group, while in the low-risk patients, this association became
non-signiﬁcant. The effect of repeated diastolic blood pressure
measurements showed an opposite shift, increasing in the low-
risk group and loosing signiﬁcance in the high-risk group. For the
intensiﬁcation of blood-pressure-lowering medication, the effect
of the last value of diastolic blood pressure on intensiﬁcation
remained signiﬁcant only in the low-risk stratum. The associa-
tion between the last value of total cholesterol and treatment
intensiﬁcation of lipid-lowering medication increased in the
high-risk group and decreased in the low-risk stratum.
DISCUSSION
The decision to modify cardiometabolic treatment in patients
with diabetes was in part inﬂuenced by repeated elevated risk
factor levels. Starting antihypertensive treatment and intensi-
fying oral blood-glucose-lowering medication were affected by
repeated measurements above target level. Surprisingly, starting
treatment for any of the risk factors was more likely in patients
with a higher medication burden. The found associations
between predictors and outcomes, although they occurred
subsequent to each other in time, are not necessarily causal.
A treatment decision based on the last measurement in
combination with recent history acknowledges the intrinsic
variation of physiological measurement as well as other
variation.28e30 Although it has been suggested that physicians
take more than one measurement into account,12 18 19 we could
only conﬁrm this for the start of antihypertensive treatment and
the intensiﬁcation of oral blood-glucose-lowering medication.
One could expect that a delay in acting on elevated risk factor
levels is less desirable in high-risk patients. The models stratiﬁed
on overall cardiovascular risk indeed showed that the impact of
repeated high levels of diastolic blood pressure on the decision to
start treatment was not signiﬁcant in high-risk patients. No such
differences were observed for the other treatment decisions. We
also did not ﬁnd a signiﬁcant contribution of other risk factor
levels on any of the treatment decisions, suggesting overall
cardiovascular risk was generally not considered. This conﬁrms
previous ﬁndings showing that treatment changes were
mainly determined by elevated levels of the corresponding risk
factor.31 32
We observed an inﬂuence of both systolic and diastolic blood
pressure values on the antihypertensive treatment decisions.
Despite the fact that systolic blood pressure has become more
important for treatment recommendations, diastolic blood
pressure appeared still relevant for the GPs in our study. The
decision to start treatment was inﬂuenced by the number of
previous diastolic blood pressure measurements above target
level. Studies looking only at the most recent measurements
may therefore have underestimated the inﬂuence of diastolic
blood pressure on doctors’ decision making.9
According to physicians, concerns about medication burden
and compliance are important when deciding to prescribe drug
treatment to patients using multiple drugs.8 13 In our study, the
number of concurrently used drugs was not a barrier but instead
positively associated with the start of medication. Previous
studies conducted in the USA showed somewhat conﬂicting
results, where a higher number of concurrently used other drugs
was either found negatively associated or not associated with
treatment modiﬁcations.9 18 This discrepancy could be explained
by differences in drug reimbursement between the countries
studied: In The Netherlands, there is no ﬁnancial burden for the
patient. Also, our study showed that in many cases, drug treat-
ment could be intensiﬁed without adding another drug.
Furthermore, adding a drug might not be a problem for patients
already used to a multiple-drug scheme.33
In contrast to antihypertensives and glucose-lowering
medication, decisions to start and intensify lipid-lowering
medication were not inﬂuenced by repeated risk factor
measurements. Relatively few patients received lipid-lowering
medication, and intensiﬁcation of such medication was
uncommon. As was shown in other studies, GPs may have
several reservations for prescribing lipid-lowering medication,
such as expecting very few beneﬁts in older patients or in
patients with near-goal lipid levels.34 35 Also, patients can be
reluctant to take them. The results from our study show that the
reluctance to prescribe lipid-lowering drugs is not affected by
repeated elevated lipid levels and might be seen as a decision of
the GP not to prescribe lipid-lowering medication in some of their
patients.
This study has some limitations. The GPs in our study may
not be representative of all GPs in The Netherlands. They
participated voluntarily in a regional diabetes project, which
could have resulted in a group of GPs included with a higher
interest in diabetes than in general. The data used in this study
come from the ﬁrst retrospective data collection at these prac-
tices, and therefore alteration of the GPs’ prescribing behaviour
due to the participation in the regional project was not possible.
The level of prescribing in our GP population was similar to other
populations in The Netherlands.31e36 It can be questioned
whether the results are applicable to other countries. Although
similar low rates of treatment and treatment intensiﬁcation have
been observed in other studies,36e39 there may be intrinsic
differences in the healthcare system that inﬂuence the motiva-
tion and rate of treatment modiﬁcations. Furthermore, there can












Age 100.0 66 (12)
Female, % 100.0 56
Diabetes duration 99.0 4 (6)y
Systolic blood pressure 81.8 4 (2) 147 (20)
Diastolic blood pressure 81.7 4 (2) 81 (10)
HbA1c 76.9 3 (2) 7.3 (1.3)
Total cholesterol 74.8 2 (3) 5.2 (1.0)
Body mass index 57.9 3.5 (1) 29.6 (5.4)








*12 months for all factors except total cholesterol (24 months).
yMedian (IQR).
HbA1c, Haemoglobin A1c; IQR, interquartile range.
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be unmeasured factors at the level of the GP (eg, time per
consultation, GPs’workload) and the patient (eg, social economic
status, educational level) that may inﬂuence the decisions.
Our reliance on data collection from medical records has both
strengths and weaknesses. Incomplete registration may affect
our ﬁndings. In general, prescribing data and test results are
reliably documented in electronic records, but underregistration
of lifestyle data is common.40 Risk factor measurements,
however, are not always routinely assessed by the GPs. In our
analyses, we assume that the GPs prescribing decisions were not
inﬂuenced by test results that were not noted in the medical
records.
Furthermore, we were unable to correct for several potentially
relevant confounders due to poor registration in the patient ﬁles,
such as smoking, contraindications or patients’ non-adherence or
refusal of treatment, which may have resulted in an underesti-
mation of the effect of risk factor information on the likelihood
of treatment modiﬁcation. One study in the UK showed that
a patient’s smoking status may affect the GP ’s decision to start
lipid-lowering medication.41 Medication adherence has been
found both positively and negatively related to subsequent
treatment modiﬁcations.42e44 In a recent study, however, poor
medication adherence was found to be irrelevant for the decision
to intensify antihypertensive treatment.45
A strength of our study is that it analyses the effect of
repeated risk factor measurements and concurrent medication
on actual prescribing without relying on survey methods that
may inﬂuence the outcomes.
This study shows that waiting for the next measurement
before deciding to modify treatment can explain part of the
observed undertreatment for hypertension and hyperglycaemia
that has been called “clinical inertia”.15 38 The low levels of
treatment modiﬁcation for lipid-lowering drugs, however, cannot
be explained by an awaiting attitude. Overall, cardiovascular risk
seems to have some impact on the decision to start or intensify
treatment. An alerting system on the combined exposure to
elevated risk factors may be helpful to improve current treat-
ment. Furthermore, quality assessment of physician performance
evaluations based only on the most recent measurement of a risk
factor may lead to an inaccurate view on the decision-making
process.
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